BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 24447114)

  • 1. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
    Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
    Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B;
    J Allergy Clin Immunol; 2010 Jul; 126(1):105-11.e5. PubMed ID: 20542320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
    Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
    Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Aberer W; Birnbaum J; Bodzenta-Lukaszyk A; Bonifazi F; Bucher C; Campi P; Darsow U; Egger C; Haeberli G; Hawranek T; Körner M; Kucharewicz I; Küchenhoff H; Lang R; Quercia O; Reider N; Severino M; Sticherling M; Sturm GJ; Wüthrich B
    J Allergy Clin Immunol; 2009 Nov; 124(5):1047-54. PubMed ID: 19895993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
    Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
    Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected.
    Bonadonna P; Zanotti R; Pagani M; Bonifacio M; Scaffidi L; Olivieri E; Franchini M; Reccardini F; Costantino MT; Roncallo C; Mauro M; Boni E; Rizzini FL; Bilò MB; Marcarelli AR; Passalacqua G
    J Allergy Clin Immunol Pract; 2018; 6(4):1368-1372. PubMed ID: 29258788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
    Ruëff F; Przybilla B; Biló MB; Müller U; Scheipl F; Seitz MJ; Aberer W; Bodzenta-Lukaszyk A; Bonifazi F; Campi P; Darsow U; Haeberli G; Hawranek T; Küchenhoff H; Lang R; Quercia O; Reider N; Schmid-Grendelmeier P; Severino M; Sturm GJ; Treudler R; Wüthrich B
    PLoS One; 2013; 8(5):e63233. PubMed ID: 23700415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients.
    Niedoszytko M; Bonadonna P; Oude Elberink JN; Golden DB
    Immunol Allergy Clin North Am; 2014 May; 34(2):365-81. PubMed ID: 24745680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
    Haeberli G; Brönnimann M; Hunziker T; Müller U
    Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hymenoptera venom immunotherapy and field stings.
    Lang R; Hawranek T
    J Investig Allergol Clin Immunol; 2006; 16(4):224-31. PubMed ID: 16889279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).
    Ruëff F; Bauer A; Becker S; Brehler R; Brockow K; Chaker AM; Darsow U; Fischer J; Fuchs T; Gerstlauer M; Gernert S; Hamelmann E; Hötzenecker W; Klimek L; Lange L; Merk H; Mülleneisen NK; Neustädter I; Pfützner W; Sieber W; Sitter H; Skudlik C; Treudler R; Wedi B; Wöhrl S; Worm M; Jakob T
    Allergol Select; 2023; 7():154-190. PubMed ID: 37854067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mastocytosis and insect venom allergy.
    Bonadonna P; Zanotti R; Müller U
    Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
    Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
    Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis.
    González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L
    Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of Hymenoptera venom allergy.
    Biló BM; Rueff F; Mosbech H; Bonifazi F; Oude-Elberink JN;
    Allergy; 2005 Nov; 60(11):1339-49. PubMed ID: 16197464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.